-- Payment includes $9.75 million cash and $3.25 million in Imugene Limited ordinary shares-- --The addition of this cash further reinforces Precision’s expected cash runway into the second half of 2026-- DURHAM, N.C. --(BUSINESS WIRE)--Sep. 3, 2024-- Precision BioSciences, Inc.